New Pharmaceuticals market report from Global Markets Direct: "Protalix BioTherapeutics, Inc. - Product Pipeline Review - 2013"
Boston, MA -- (SBWIRE) -- 10/08/2013 -- Global Market Direct's pharmaceuticals report, "Protalix BioTherapeutics, Inc. - Product Pipeline Review - 2013" provides data on the Protalix BioTherapeutics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, Protalix BioTherapeutics, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Protalix BioTherapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.
- Protalix BioTherapeutics, Inc. - Brief Protalix BioTherapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Protalix BioTherapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Protalix BioTherapeutics, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Protalix BioTherapeutics, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
View Full Report Details and Table of Contents
Reasons to Get This Report
- Evaluate Protalix BioTherapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Protalix BioTherapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Protalix BioTherapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Protalix BioTherapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Protalix BioTherapeutics, Inc. and identify potential opportunities in those areas.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Northwest Biotherapeutics, Inc. - Product Pipeline Review - 2013
- CardioVascular BioTherapeutics, Inc. - Product Pipeline Review - 2013
- Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2013
- Alethia Biotherapeutics Inc. - Product Pipeline Review - 2013
- Healthpoint Biotherapeutics - Product Pipeline Review - 2013
- Gaucher's Disease - Pipeline Review, H1 2013
- Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2013
- Organophosphate And Carbamate Poisoning - Pipeline Review, H2 2013
- Bone Cancer - Pipeline Review, H1 2013
- Bone Metastasis - Pipeline Review, H2 2013